Physician profile
Larry E Smith
NPI 1548297195
$423.62
in general payments reported to CMS, 2019-2025
16 companies · $58.56 in 2025
The $58.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2023: $80.60 · 2024: $44.03 · 2025: $58.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $83.75 | 2019 | |
| Novo Nordisk INC | $63.09 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $31.26 | 2019 | |
| Octapharma USA, INC. | $29.71 | 2025 | Cutaquig |
| Astellas Pharma US INC | $26.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.87 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.19 | 2024 | Xifaxan |
| Kedrion Biopharma, INC. | $21.84 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Kyowa Kirin, INC. | $18.36 | 2023 | |
| Gilead Sciences, INC. | $16.98 | 2019 | |
| Abbott Laboratories | $16.03 | 2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $15.50 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.13 | 2019 | |
| Lilly USA, LLC | $13.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.55 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.